Correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia

Abstract

To assess the correlation between metabolic syndrome and clinical progression in patients with benign prostatic hyperplasia (BPH). A total of 382 BPH patients with lower urinary tract symptoms were divided into two groups according to whether or not there was a diagnosis of metabolic syndrome (MS). MS was defined by the International Diabetes Federation (IDF) in 2005. Abdominal B-ultrasound was used to measure the total volume of prostate (TP) and its average annual growth rate was calculated. Body mass index, waist-hip ratio, blood biochemistry, blood pressure, blood glucose and other indicators were compared in these two groups of patients with regards to the clinical progression associated with BPH. A total of 187 MS cases were found in 382 (48.59%) BPH patients. It showed a higher body mass index, high glycemia, high triglycerides, high blood pressure and high IPSS, TP and PSA levels. Also it showed a higher occurrence of surgical rate (P < 0.05); its average annual growth rate of TP was significantly higher than those without MS (1.0 vs 0.64 ml/yr, P < 0.05). TP average annual growth rate and IPSS score are found significantly correlated with blood glucose and triglyceride levels (P < 0.01). Metabolic syndrome affects the clinical progression in patients with BPH. Clinical attention should be paid.